Reduced expression of cerebral metabotropic glutamate receptor subtype 5 in men with fragile X syndrome.

Table S1. Concomitant medications of participants with fragile X syndrome from the Institute for Neurodegenerative Disorders. Table S2. Demographic and clinical characteristics of participants from the Institute for Neurodegenerative Disorders (IND). All participant are non-Hispanic. Table S3. Demographic and clinical data of participants from Johns Hopkins University (JHU). Table S4. Genetic and psychological assessments of participants from the Institute for Neurodegenerative Disorders. Table S5. Genetic and psychological assessments of participants with fragile X syndrome and family members from Johns Hopkins University. Table S6. Positron emission tomography (PET) data and analyses for participants from the Institute for Neurodegenerative Disorders. Table S7. Positron Emission Tomography (PET) data and analysis of participants from Johns Hopkins University. The authors thank Flora Tassone, Ph.D., Department of Biochemistry and Molecular Medicine, School of Medicine, UC Davis Health, Sacramento, California, for providing genetic and protein data about participants.